Though some experimental agents, such as thymosin (NCT00711620) and granulocyte-macrophage colony stimulating factor (NCT00252915), are being tested in clinical trials to reconstitute immune responsiveness in patients with severe sepsis, an effective treatment is still unavailable until now. The gene discussed is CSF2; the disease is Sepsis.